Comparing QLS32015 to standard treatments for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with multiple myeloma that can be measured with blood or urine tests.
- You have had at least 3 prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
- You do not have active plasma cell leukemia or light chain amyloidosis.
- Your disease is not resistant to pomalidomide or selinexor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
This trial tests a new drug called QLS4131 for people with multiple myeloma that has returned or not responded to treatment. It's a first-in-human study to see if the drug is safe and how well it works.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This study tests a new drug combination called QLS4131 paired with other medications to treat multiple myeloma, plasma cell leukemia, and light-chain amyloidosis—blood cancers caused by abnormal plasma cells. The goal is to see if this combination can help control these diseases better than current treatments.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.